<DOC>
	<DOCNO>NCT01031303</DOCNO>
	<brief_summary>The purpose study provide immunogenicity safety information sanofi pasteur 's DTacP-IPV combine vaccine ( TETRAXIM™ ) booster dose 4th 6th year life child previously receive Study E2I34 ( NCT 00255021 ) , sanofi pasteur DTacP-IPV// PRP~T vaccine ( PENTAXIM™ ) three-dose primary booster vaccination . Primary Objective : - To assess immunogenicity term seroprotection rate ( Diphtheria , Tetanus , Polio type 1 , 2 3 ) seroconversion/vaccine response rate acellular Pertussis antigen ( Pertussis toxoid [ PT ] , Filamentous Haemagglutinin [ FHA ] ) sanofi pasteur 's DTacP-IPV ( Tetraxim™ ) vaccine , one month booster dose give 4 6 year age . Secondary Objectives : - To describe antibody persistence term anti-pertussis antibody level ( anti-PT , -FHA ) term seroprotection rate GMTs Diphtheria , Tetanus , Poliovirus type 1 , 2 3 , administration booster dose ( Visit 1 ) subject 4-6 year age . - To assess immunogenicity term seroprotection rate ( Diphtheria , Tetanus , Polio type 1 , 2 3 ) seroconversion/ vaccine response rate acellular Pertussis antigen ( PT , FHA ) sanofi pasteur 's DTacP-IPV ( Tetraxim™ ) vaccine , one month administration booster dose give 4 6 year age . - To describe safety booster dose study vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety TETRAXIM™ Given Booster Dose 4 6 Years Age</brief_title>
	<detailed_description>All participant previously complete three-dose primary booster vaccination study E2I34 ( NCT 00255021 ) contact enroll study receive sanofi pasteur 's DTacP IPV combine vaccine ( Tetraxim™ ) 4 6 year age . Participants receive study vaccine [ sanofi pasteur 's DTacP-IPV vaccine ( TETRAXIM™ ) ] 4 6 year age ( visit 1 ) .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 46 year inclusive day inclusion Child complete threedose vaccination booster vaccination DTacPIPV//PRP~T combine vaccine ( PENTAXIM™ ) study E2I34 Informed consent form sign parent ( ) legal representative Able attend schedule visit comply trial procedure Exclusion Criteria : Participation another clinical trial 4 week precede trial inclusion Planned participation another clinical trial present trial period Congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy Systemic hypersensitivity vaccine component history life threaten reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion Blood bloodderived product receive past current plan administration trial ( include immunoglobulin ) Any vaccination 4 week precede trial vaccination History diphtheria , tetanus , pertussis , poliomyelitis infection ( confirm either clinically , serologically microbiologically ) Clinical know serological evidence systemic illness include Hepatitis B , Hepatitis C and/or Human immunodeficiency virus ( HIV ) infection Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis disease infection trial vaccine another vaccine completion previous study E2I34 Thrombocytopenia bleed disorder contraindicate intramuscular vaccination History of/current major neurological disease seizure Febrile illness ( temperature ≥ 38°C ) acute illness day inclusion . Serious severe reaction previous dose vaccine contain pertussis antigen , encephalopathy ( without convulsion ) 7days follow previous administration pertussis contain vaccine , temperature 39.5°C within 48 hour follow vaccine injection , due another identifiable cause inconsolable cry equal 3 hour within 48 hour follow vaccine injection , hypotonic hyporesponsive episode within 48 hour follow vaccine injection , seizures without fever within 3 day follow vaccine injection .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>PENTAXIM™</keyword>
	<keyword>TETRAXIM™</keyword>
</DOC>